Semaglutide · 26 May 2026
Semaglutide: The GLP-1 Agonist at the Centre of Metabolic Research
Essential Peptides Au · Journal · 4 min read
A GLP-1 receptor agonist. The subject of extensive metabolic and glycaemic regulation literature, and the compound responsible for much of the recent mainstream attention on the GLP-1 class. Research contexts span glucose regulation, appetite signalling, and cardiovascular endpoints, with a publication volume that now dwarfs most other peptides in this field map.
Mechanism in brief
Semaglutide binds the GLP-1 receptor (GLP-1R), a class B GPCR, and activates Gs-coupled adenylyl cyclase to elevate intracellular cAMP, with downstream signalling proceeding via PKA-mediated phosphorylation of CREB and other substrates. A C18 fatty diacid chain, linked at Lys26 via a short spacer, confers albumin binding that extends circulating half-life to roughly one week in pharmacokinetic models — making it a standard comparator in peptide persistence and receptor-occupancy kinetics.
In current research
Its high GLP-1R selectivity, relative to the glucagon or GIP receptors, makes it a clean single-pathway reference standard in multi-receptor comparator assays. Cross-panel comparisons with tirzepatide and other incretin analogs are a common way to distinguish single- from dual- and triple-pathway signalling profiles.
View compound
Semaglutide in the catalogue
Related reading
For research use only. This article is provided for research and educational purposes and does not describe or imply therapeutic use. None of these compounds are for human or veterinary consumption.